Diana Ernst

The approval of Opdivo Qvantig was supported by data from the randomized, open-label phase 3 CheckMate-67T study (ClinicalTrials.gov Identifier:

An expert panel consisting of dietitians, doctors, nutritional epidemiologists, chefs, and weight loss researchers examined the evidence behind 38 diets to come up with the final results. Rather than ranking the diets as in previous years, US News shifted to a 5-point rating system.

SPN-830 for Adults With Parkinson Disease Brexpiprazole Plus Sertraline for Post-Traumatic Stress Disorder

Rhythm Pharmaceuticals announces FDA approval of Imcivree® (setmelanotide) for patients as young as 2 years old. News release. Rhythm Pharmaceuticals December 20, 2024.

FDA approves Zepbound® (tirzepatide) as the first and only prescription medicine for moderate-to-severe obstructive sleep apnea in adults with obesity.

GSK'227 (also known as HS-20093) is a novel antibody-drug conjugate (ADC) composed of a fully human anti-B7-H3 monoclonal antibody covalently linked to a topoisomerase inhibitor payload. The Breakthrough Therapy designation is supported by data from the open-label, phase 2 ARTEMIS-002 trial (ClinicalTrials.gov Identifier:

No reason was provided for the discontinuation. Zinplava (bezlotoxumab) injection will be discontinued as of January 31, 2025, according to the Food and Drug Administration's (FDA) drug shortages tracker.

The Food and Drug Administration (FDA) has approved Unloxcyt™ (cosibelimab-ipdl) for the treatment of adults with metastatic cutaneous squamous cell

Cardiovascular Disease Dermatological Disorders Diagnostic Agents Endocrine Disorders Gastrohepatic Disorders

US Food and Drug Administration. FDA requires Guillain-Barré syndrome (GBS) warning in the prescribing information for RSV vaccines Abrysvo and Arexvy. January 7, 2024.